The drug is designed to hit the target without affecting healthy tissues. In terms of effectiveness, it is like a bomb. Why?
In the laboratory of Research Institute of Clinical and Experimental Lymphology of the Siberian Branch of the Russian Academy of Sciences, chemists and biologists are working together to create a weapon against cancer. The complex of compounds can hit right on target.
Anastasia Solovyeva, Head of the laboratory at the Research Institute of Clinical and Experimental Lymphology, said:
“In their development, tumor and tumor cells use many signaling pathways and mechanisms to deceive the immune system and, instead of fighting them, the immune system facilitates their spread.”
Cancer is resistant to drugs, and it should be dealt with on several fronts. The so-called “multimodal complex” which is being developed by Siberian scientists is a real bomb. Its nanoparticle includes several types of weapons, such as active oxygen, heat energy, and medicine. Through the human vein, the complex is directed towards the tumor, and then a ray of light comes into action.
“This is about creating compounds that can penetrate deep into cancerous tumors and have photodynamic activity. X-rays activate such compounds, as they easily pass through the tissues,” commented Kirill Vorobyev, a journalist familiar with the research
An X-ray beam acts as a detonator on the surface of nanoparticle. It triggers the reaction.
Mikhail Shestopalov, senior researcher at A.V. Nikolaev Institute of Inorganic Chemistry of Siberian Branch of the Russian Academy of Sciences, said:
“With X-ray radiation alone, we trigger the whole chain: activate the cluster complex of photodynamic therapy, which in turn activates the “gold” (photothermotherapy), meanwhile, the conventional chemotherapy is also used.”
At the first stage of reaction, the cells release active oxygen followed by a powerful heat wave and explosion, which destroy the tumor. Non-invasive treatment is a promising research area. The question is who will be the first to present its finished product to the world. Scientists at the Siberian Branch of the Russian Academy of Sciences already started their first trials.